Literature DB >> 10634559

Homologous penetrating central limbo-keratoplasty (HPCLK) in bilateral limbal stem cell insufficiency.

T Reinhard1, R Sundmacher, H Spelsberg, C Althaus.   

Abstract

PURPOSE: Bilateral stem cell deficiency can be overcome only by keratoplasty plus additional homologous limbal transplantation. We have four years' experience with a new surgical one-stage procedure, homologous penetrating central limbo-keratoplasty (HPCLK).
METHODS: A clinical trial was performed in order to evaluate the effectiveness of this new method. The first 25 eyes after HPCLK for limbal stem cell deficiency have been followed for more than 12 months. The eccentrically trephined unmatched grafts contained 40% limbus and were transplanted centrally in the host. Systemic cyclosporin A (CSA) was administered for at least one year. Central clear graft survival was the main outcome criterion.
RESULTS: 18 grafts failed, mostly because of postoperative surface disorders. Seven grafts have remained centrally clear 12-41 months after HPCLK.
CONCLUSIONS: In the majority of the grafts the transplanted limbal stem cells underwent immune destruction. The survival of seven grafts, however, shows that HPCLK is principally a promising new procedure. Further progress can be expected from the use of well HLA-matched grafts instead of unmatched grafts and from further improved systemic immune modulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10634559     DOI: 10.1034/j.1600-0420.1999.770611.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  12 in total

Review 1.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 2.  [Perspectives and current state in limbal stem cell transplantation].

Authors:  P Eberwein; T Reinhard
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

Review 3.  [Ocular surface reconstruction in limbal stem cell insufficiency: transplantation of limbal tissue].

Authors:  P Eberwein; T Reinhard
Journal:  Ophthalmologe       Date:  2012-09       Impact factor: 1.059

4.  Long-term results of allogenic penetrating limbo-keratoplasty: 20 years of experience.

Authors:  S J Lang; D Böhringer; G Geerling; T Reinhard
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

5.  Diagnostic criteria for limbal stem cell deficiency before surgical intervention-A systematic literature review and analysis.

Authors:  Qihua Le; Tulika Chauhan; Sophie X Deng
Journal:  Surv Ophthalmol       Date:  2019-07-02       Impact factor: 6.048

6.  ALT (allogeneic limbal transplantation): a new surgical technique for limbal stem cell deficiency.

Authors:  Anja Viestenz; Christiane Kesper; Thomas Hammer; Joana Heinzelmann; Sabine Foja; Arne Viestenz
Journal:  Int Ophthalmol       Date:  2022-08-19       Impact factor: 2.029

7.  [Long-term results of homologous penetrating limbokeratoplasty in total limbal stem cell insufficiency after chemical/thermal burns].

Authors:  Thomas Reinhard; T Kontopoulos; P Wernet; J Enczmann; R Sundmacher
Journal:  Ophthalmologe       Date:  2004-07       Impact factor: 1.059

Review 8.  [Keratoplasty: laminate or penetrate? Part 2: lamellar keratoplasty].

Authors:  P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2009-07       Impact factor: 1.059

9.  Transplantation of human embryonic stem cells onto a partially wounded human cornea in vitro.

Authors:  Charles Hanson; Thorir Hardarson; Catharina Ellerström; Markus Nordberg; Gunilla Caisander; Mahendra Rao; Johan Hyllner; Ulf Stenevi
Journal:  Acta Ophthalmol       Date:  2012-01-26       Impact factor: 3.761

10.  Simultaneous transplantation of limbal stem cells may reduce recurrences of granular dystrophy after corneal transplantation: 2 long-term case reports.

Authors:  Stefan J Lang; Philipp Eberwein; Helga Reinshagen; Thomas Reinhard; Rainer Sundmacher
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.